


TOZAL[®] Clinical Study

Proven to Improve or Stabilize Vision for AMD

- **56.7% Experienced Improved Vision**
- **20% Experienced Stable Vision**
- **23.3% Continued to Worsen (Natural Progression: No Worse Than Control)**



Results of TOZAL[®] study were based on AREDS study as control and AREDS results were compared to placebo.

Only 2 formulas have completed clinical studies and passed peer review: AREDS and TOZAL[®].

Patients treated with TOZAL[®] gained an average of .5 lines while those treated with the control lost an average of 1.5 lines.

TOZAL is a registered trademark of Atlantic Medical, Inc.

PreserVision is a registered trademark of BAUSCH & LOMB PHARMACEUTICALS, INC